• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:薛晶,仲宣惟,王杉.中美药品进口检验制度比较[J].药学研究,2026,45(6):711-715[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1144次   下载 627次 本文二维码信息
码上扫一扫!
中美药品进口检验制度比较
薛晶,仲宣惟,王杉
字体:加大+|默认|缩小-
(中国食品药品检定研究院,北京 102629)
摘要:
目的 系统比较中美药品进口检验制度,为我国制度优化提供参考。方法 从制度框架、口岸流程、技术标准与执法工具、特殊品类四个维度进行比较分析。结果 两国均以风险管控为核心建立分级处置机制,口岸流程基本相似。主要差异体现在药典标准的强制性和执法工具的先进性方面。特殊品类方面,我国允许进口罕见病药品在正式获批前先行使用,对生物制品实施更广泛的批签发,对中药材和中成药逐批检验;美国侧重罕见病药品上市前激励,生物制品以过程管控为主,中药材和中成药按膳食补充剂管理。结论 总体而言中美制度相似度较高。我国可在加入PIC/S、开发智能拦截工具、优化罕见病药品通关、强化上市后全链条监管等方面持续改进,以更好平衡药品进口的安全与效率。
关键词:  药品进口  中美比较  监管理念  检验制度
DOI:10.13506/j.cnki.jpr.2026.06.016
基金项目:
收稿日期:2026-04-20   修回日期:2026-05-18  
Comparative study on the drug import inspection systems between China and the United States
XUE Jing,ZHONG Xuanwei,WANG Shan
(National Institutes for Food and Drug Control, Beijing 102629, China)
Abstract:
Objective A systematic comparison was made between the drug import inspection systems of China and the United States to provide a reference for the optimization of China's system. Methods A comparative analysis was conducted from four dimensions: institutional framework, port procedures, technical specifications and enforcement tools. Results It was found that both countries had established hierarchical management mechanisms with risk control as the core, and the port procedures were basically similar. The main differences were manifested in the mandatory nature of pharmacopoeia and the sophistication of enforcement tools. Regarding special categories, imported orphan drugs were permitted for clinical use prior to formal market authorization in China, while pre-market incentives were emphasized in the United States; for biological products, a more extensive batch release system was enforced in China, whereas process control was primarily relied upon in the United States; and for Chinese medicinal materials and Chinese medicines, batch-by-batch inspection was conducted in China, while dietary supplements were regulated as they are in the United States. Conclusion Overall, a high degree of similarity was observed between the systems of China and the United States. Continuous improvements could be made by China in joining PIC/S, developing intelligent interception tools, optimizing customs clearance for orphan drugs, and strengthening post-market whole-chain supervision, so that a better balance between the safety and efficiency of drug imports could be achieved.
Key words:  Drug import  China-U.S. comparison  Regulatory system  Inspection management
今日访问量:2273    总访问量:55338614
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司